An open clinical trial of reboxetine in the treatment of social phobia

dc.contributor.authorAtmaca, M
dc.contributor.authorTezcan, E
dc.contributor.authorKuloglu, M
dc.date.accessioned2026-08-12T17:26:22Z
dc.date.issued2003
dc.departmentFırat Üniversitesi
dc.description.abstract[Abstract Not Available]
dc.identifier.doi10.1097/01.jcp.0000085419.74359.a4
dc.identifier.endpage419
dc.identifier.issn0271-0749
dc.identifier.issue4
dc.identifier.pmid12920422
dc.identifier.scopus2-s2.0-0043135269
dc.identifier.scopusqualityQ2
dc.identifier.startpage417
dc.identifier.urihttps://doi.org/10.1097/01.jcp.0000085419.74359.a4
dc.identifier.urihttps://hdl.handle.net/11508/54801
dc.identifier.volume23
dc.identifier.wosWOS:000184554700018
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Clinical Psychopharmacology
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectDouble-Blind
dc.subjectMoclobemide
dc.subjectPhenelzine
dc.titleAn open clinical trial of reboxetine in the treatment of social phobia
dc.typeLetter

Dosyalar